6533b7defe1ef96bd12766c5

RESEARCH PRODUCT

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients

Bengt GlimeliusJacqueline OatesAndrew WotherspoonJens C. HahneHazel LoteHazel LoteAndrea LampisDomenico ZitoNicola ValeriNicola ValeriIan ChauDiana TaitJosep TaberneroRuwaida BegumDavid CunninghamDavid Gonzalez De CastroAndrés CervantesGina BrownFrancesco SclafaniChiara BraconiChiara BraconiSanna Hulkki WilsonClare PeckittMichele GhidiniZakaria Eltahir

subject

AdultMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyPathologyGenotypeColorectal cancermedicine.medical_treatmentOriginal ManuscriptSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmicroRNAmedicineHumansOncology & CarcinogenesisProgression-free survivalNeoadjuvant therapyAgedRetrospective StudiesCetuximabRectal Neoplasmsbusiness.industryChemoradiotherapyGeneral MedicineMiddle Agedmedicine.diseaseChemotherapy regimenNeoadjuvant Therapy3. Good healthRadiation therapyMicroRNAs030104 developmental biology030220 oncology & carcinogenesisFemalebusiness1112 Oncology And Carcinogenesismedicine.drug

description

Summary Analysis of a polymorphism in mature microRNA-608 (rs4919510) in rectal cancer patients enrolled in a randomized phase II clinical trial identified patient subpopulations who might benefit from the use of an intensified neo-adjuvant treatment strategy with Cetuximab.

yearjournalcountryeditionlanguage
2016-01-01
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=3107